Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
BIOSION INC. holds a company patent portfolio focused on Biotechnology & Pharmaceuticals. There is currently 1 pending office action associated with this portfolio. This action is being handled by 1 distinct examiner and is situated within 1 distinct art unit. This reflects a very specific and limited scope of current prosecution activity. For a practitioner, this means that the prosecution strategy is entirely dependent on the interaction with this 1 distinct examiner and the specific standards of the 1 distinct art unit.
The busiest examiner for BIOSION INC. is JOHNSON, TIRONE DEREK, who has 1 busiest examiner pending action. As the total count of pending office actions is 1, JOHNSON, TIRONE DEREK is the sole official responsible for the company's current patent review. The involvement of only 1 distinct art unit further suggests that the pending matter falls within a specific technical niche of the Biotechnology & Pharmaceuticals field. This concentration requires a targeted approach to satisfy the examiner's requirements, as the outcome of the 1 pending office action will define the current success of the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHNSON, TIRONE DEREK | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18698680 | ANTI-ILT4 AND ANTI-PD-1 BISPECIFIC CONSTRUCTS | JOHNSON, TIRONE DEREK | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18698680 | ANTI-ILT4 AND ANTI-PD-1 BISPECIFIC CONSTRUCTS | JOHNSON, TIRONE DEREK | 1675 | §112 | Non-Final OA | — | Pending | Apr 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIOSION INC. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Tirone Derek Johnson has the most, with 1 of BIOSION INC.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
